{
  "id": "mhgap#risk_safety_4b5262cd",
  "title_en": "General — Risk Safety",
  "title_vi": "General — Nguy cơ An toàn",
  "text_en": "3. Recommendations y There is low- to moderate-quality evidence that Research gaps the safety profile of levetiracetam was better y Most of the research is from HICs. Further studies are than fosphenytoin in terms of less requirement needed in LMICs. for intubation. y Further research is needed on the proportion of y There is low- to moderate-quality evidence that electrographic seizures after resolution of clinical the safety profile of sodium valproate was better seizures in status epilepticus with different ASMs than phenytoin for cardiovascular adverse effects, in children. and better than fosphenytoin in terms of less y As the outcome is highly dependent on the etiology requirement for intubation. of status epilepticus, trials in adults/children with y The advantages of sodium valproate include a status epilepticus of specific etiology, such as smaller risk for cardiorespiratory side-effects. infectious etiology (e.g. encephalitis), may be useful y Sodium valproate has, however, been associated to improve understanding. with risks for hepatotoxicity and pancreatitis. It is contraindicated in individuals with liver disease, Implementation considerations which may not be evident when the person is y The choice of medicine is affected by a number of brought in convulsing and needs emergency factors, including availability, cost and side-effects. treatment. Also, sodium valproate is contraindicated y There are feasibility and affordability issues; in inherited metabolic – including mitochondrial intravenous fosphenytoin is not currently on the – disorders, which may manifest in children with WHO model list of essential medicines for children seizures and status epilepticus. (EMLc) (132). y Phenobarbital may cause sedation and respiratory y Children treated for established status epilepticus depression, and the risk may be increased if it is require monitoring and may require ventilatory used after benzodiazepines. support; thus, tertiary/secondary care is necessary. y Phenytoin is associated with risks for arrhythmia y Delay in initiation and underdosing has been and hypotension, and it is difficult to administer in observed in treatment of status epilepticus. To particular settings. terminate status epilepticus as quickly as possible y The recommendation that sodium valproate is not medicines should be given in recommended recommended in women and girls of childbearing dosages. There is a need to increase awareness of potential because of potential",
  "gloss_vi": "3. recommendations y there is low- to moderate-quality evidence that research gaps the an toàn profile of levetiracetam was better y most of the research is from hics.",
  "source": "WHO mhGAP-IG 2023",
  "url": "https://www.who.int/",
  "lang": "en",
  "axes": {
    "type": [
      "clinical",
      "everyday"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "risk_safety",
      "psychoeducation",
      "do_not_do",
      "management"
    ],
    "life_topics": [
      "stress"
    ],
    "advice_section": [],
    "audience": [],
    "risk_band": "low"
  },
  "index_text": "General — Risk Safety General — Nguy cơ An toàn 3. Recommendations y There is low- to moderate-quality evidence that Research gaps the safety profile of levetiracetam was better y Most of the research is from HICs. Further studies are than fosphenytoin in terms of less requirement needed in LMICs. for intubation. y Further research is needed on the proportion of y There is low- to moderate-quality evidence that electrographic seizures after resolution of clinical the safety profile of sodium valproate was better seizures in status epilepticus with different ASMs than phenytoin for cardiovascular adverse effects, in children. and better than fosphenytoin in terms of less y As the outcome is highly dependent on the etiology requirement for intubation. of status epilepticus, trials in adults/children with y The advantages of sodium valproate include a status epilepticus of specific etiology, such as smaller risk for cardiorespiratory side-effects. infectious etiology (e.g. encephalitis), may be useful y Sodium valproate has, however, been associated to improve understanding. with risks for hepatotoxicity and pancreatitis. It is contraindicated in individuals with liver disease, Implementation considerations which may not be evident when the person is y The choice of medicine is affected by a number of brought in convulsing and needs emergency factors, including availability, cost and side-effects. treatment. Also, sodium valproate is contraindicated y There are feasibility and affordability issues; in inherited metabolic – including mitochondrial intravenous fosphenytoin is not currently on the – disorders, which may manifest in children with WHO model list of essential medicines for children seizures and status epilepticus. (EMLc) (132). y Phenobarbital may cause sedation and respiratory y Children treated for established status epilepticus depression, and the risk may be increased if it is require monitoring and may require ventilatory used after benzodiazepines. support; thus, tertiary/secondary care is necessary. y Phenytoin is associated with risks for arrhythmia y Delay in initiation and underdosing has been and hypotension, and it is difficult to administer in observed in treatment of status epilepticus. To particular settings. terminate status epilepticus as quickly as possible y The recommendation that sodium valproate is not medicines should be given in recommended recommended in women and girls of childbearing dosages. There is a need to increase awareness of potential because of potential 3. recommendations y there is low- to moderate-quality evidence that research gaps the an toàn profile of levetiracetam was better y most of the research is from hics."
}